NEW YORK — Weill Cornell Medicine on Thursday announced a $1.5 billion research initiative to advance medicine through the use of new technologies and biomedical approaches.
The campaign, called We're Changing Medicine, has already received commitments totaling $750 million from key donors, Weill Cornell said. The money will be used for a range of purposes including the creation of a precision medicine program that will use genomics, data science, and other technologies to evaluate the individual drivers of disease. Investments in regenerative medicine and cellular therapeutics research, meanwhile, will help accelerate the discovery of new treatments.
The funds will also be used for investments in women's health and infectious disease research, the building of new facilities at the school including an updated biomedical research facility and a student residence hall, and to support scholarships.
"Innovation has always been a driving force for our institution, setting new standards for clinical care, research, and education that have made a lasting impact for patients around the globe," Jessica Bibliowicz, chair of the Weill Cornell Medicine Board of Fellows, said in a statement. "We are profoundly grateful to our incredible donors for sharing and supporting our health care ideals, because philanthropy is the engine by which we can realize transformational change."